Brand Name
Frovatriptan
View Brand InformationFDA approval date: March 11, 2016
Classification: Serotonin-1b and Serotonin-1d Receptor Agonist
Form: Tablet
What is Frovatriptan?
Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks., Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks., Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache. Frovatriptan succinate is a serotonin receptor agonist indicated for the acute treatment of migraine with or without aura in adults Limitations of Use, Use only after a clear diagnosis of migraine has been established , Not indicated for the prophylactic therapy of migraine , Not indicated for the treatment of cluster headache
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
